Anthracycline cardiotoxicity: new actors on the stage

Anthracyclines, including doxorubicin that was discovered in Italy over a half century ago, are widely used chemotherapeutics for the treatment of many human cancers (1). Shortly after their introduction, the cardiovascular toxicity has been reported (2), but despite decades of research, the pathogenesis of cardiotoxicity is still incompletely understood.